Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post by Massimo Di Maio, Associate Professor of Medical Oncology at Department of Oncology, University of Turin, adding:
“A good primer on complexities of measuring QOL in cancer clinical trials. TLDR: QOL = important pt-centered outcome…but accurately and reproducibly comparing QOL b/w regimens challenging, pros/cons of dif analyses, and currently no standard methodology.
Worth a pre-ASCO25 read.”
Quoring Massimo Di Maio‘s post:
“Have a look at my review seeking to help clinicians gain familiarity with the correct reading and interpretation of QoL results in cancer clinical trials, just published in NEJM Evidence.”
Title: Reading and Interpreting Quality-of-Life Results in Cancer Trials
Author: Massimo Di Maio
Read the Full Article.
